Kuehne Nagel has received an aggregation license in the UAE, which complements a similar certification the company received in Bahrain three years ago.
According to a Kuehne + Nagel press release, the license, granted by the Ministry of Health and Prevention (MOHAP), will allow the company to aggregate and control medicines and medical supplies entering the UAE market. The certification will enable the company to track and trace healthcare products to ensure their authenticity and safety.
“All medicines and medical supplies must be recorded and registered with MOHAP before entering the UAE market in order to detect counterfeit or altered medicines and trace the illegal supply of healthcare products,” said Safa Al Khayat, pharmacist in charge at Kuehne Nagel.
To streamline the collection process, Kuehne + Nagel implemented advanced technological solutions: Automated collection stations capable of scanning 75,000 barcodes daily have replaced traditional manual methods, significantly improving efficiency and accuracy, according to the release.
Lee I’Ons, managing director, GCC+ Cluster, Kuehne+Nagel, said: “Our healthcare clients have access to comprehensive solutions, from the basics of storage, handling and last-mile delivery to a range of value-added services that leverage Kuehne+Nagel’s global healthcare supply chain expertise. At the forefront of our approach in healthcare is the understanding that at the end of every supply chain is the patient.”
The company’s 50,000-square-metre warehouse in Dubai Logistics City has 30,000 square metres of space dedicated to pharmaceuticals and is equipped with state-of-the-art cold storage and chambers to maintain optimal conditions for medicines, as well as providing a range of value-added services such as co-packing, labelling and customs clearance, the release added.
“Compared to scanning with traditional handheld scanners, our automated solutions provide efficiency and reliability, which are very important features for our customers,” Al Khayat added. “We can respond instantly to market demands while maintaining full transparency for all parties involved in the supply chain – customers, MOHAP, distributors and the end consumer – the patient.”